LEXINGTON, Mass.--(BUSINESS WIRE)--NitroMed, Inc. (NASDAQ: NTMD) today reported financial results for its first fiscal quarter ended March 31, 2007.
Total revenues for the three months ended March 31, 2007 were $3.6 million compared to $2.3 million for the same period in 2006, an increase of $1.3 million, or 54%. Sales of BiDil® (isosorbide dinitrate/hydralazine hydrochloride) accounted for all revenues during both periods.
